Search
for
Sort by
Research 151–180 of 763
- Unraveling Evolutionary Insights into AVT Peptide Conservation and Antimicrobial Motif Prediction Across Taxa
- Update on the Potential of <i>Punica granatum</i> L. Traditional Uses and Pharmacological Uses: A Review
- Serum dihydrotestosterone levels are associated with adverse myocardial remodeling in patients with severe aortic valve stenosis before and after aortic valve replacement
- The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty
- Androgen sensitivity gateway to COVID‐19 disease severity
- Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
- Hormonal Treatment of Transgender Women with Oral Estradiol
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- A Review of the Most Common Dermatologic Conditions and their Debilitating Psychosocial Impacts
- Sertoli–Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism
- Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women
- Clinical Utility of GnRH Analogues in Female Androgen Excess: Highlighting Diagnostic and Therapeutic Applications
- (PNM-35) Recurrent priapism in a sickle cell disease patient treated with gonadotropin-releasing hormone (GnRH) agonists drugs: a case report
- Affect of a six months treatment regiment of metformin (MET) on 17-hydroxyprogesterone (17P) responses to GnRH agonist (GnRH Ag) in polycystic ovary syndrome (PCOS)
- Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
- The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology
- Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- Intratesticular Control Of Steroidogenesis
- Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗
- Physiology of the Hypothalamic Pituitary Gonadal Axis in the Male
- Polycystic ovary syndrome and impact on health
- Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
- Management of Hirsutism
- Kisspeptin and LH pulsatile temporal coupling in PCOS patients
- Differential Suppression of Testosterone and Estradiol in Hirsute Women With the Superactive Gonadotropin-Releasing Hormone Agonist Leuprolide*
- Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission
- Cardiovascular Toxicities of Androgen Deprivation Therapy
- Polycystic ovary syndrome (PCOS)
- Effects of Prenatal Treatment with Antiandrogens on Luteinizing Hormone Secretion and Sex Steroid Concentrations in Adult Spotted Hyenas, Crocuta crocuta1